Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Homologous versus heterologous COVID-19 booster vaccination after autologous hematopoietic stem cell transplantation
IRCT20140818018842N24Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jul 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of PastoCovac and BBIBP-CorV in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Tehran University of Medical Sciences. Started Jul 2022; status: completed.
02
Drugs
PastoCovacBBIBP-CorV
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20140818018842N24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140818018842N24.